MK-3697
MK-3697 is a potent, selective, orally bioavailable Orexin 2 receptor (OX2R) antagonist with Ki of 1.1 nM and IC50 of 16 nM, shows exquisite selectivity over OX1R (Ki=18 uM) ; MK-3697 is orally efficacious in sleep experiments across species with high OX2R occupancy and low OX1R blockade, demonstrated excellent sleep efficacy across species, and shows potential for the treatment of insomnia.Sleep Disorder Phase 2 Discontinued.
Product Specifications
CAS Number
1224846-01-8
Product Name Alternative
MK 3697 | MK3697
Purity
>98% (HPLC)
Solubility
DMSO: 22.5 mg/mL
Smiles
COC1=C (OC) N=C (CNC (=O) C2=CC (=NC=C2C2=NC=CS2) C2=CC (C) =CN=C2) C=C1
Molecular Formula
C23H21N5O3S
Molecular Weight
447.5096
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
[2,3'-Bipyridine]-4-carboxamide, N-[ (5,6-dimethoxy-2-pyridinyl) methyl]-5'-methyl-5- (2-thiazolyl) -
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
APP (Y756) (APP, A4, AD1, Amyloid beta A4 protein, ABPP, APPI, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, N-APP, Soluble APP-alpha, Soluble APP-beta, C99, Beta-amyloid protein 42, Beta-APP42, Beta-amyloid protein 40, Beta-APP40, C83, P3 (42), P3 (40), C80, Gamma-secretase C-terminal fragment 59, Amyloid intracellular domain 59, Gamma-CTF (59), Gamma-secretase C-terminal fragment 57, Amyloid intracellular domain 57, Gamma-CTF (57), Gamma-secretase C-terminal fragment 50, Amyloid intracellular domain 50, Gamma-CTF (50), C31) (MaxLight 405) discontinued
